An Off-Label Single Arm Clinical Study to Evaluate the Efficacy and Safety of doxecitine and doxribtimine in Adult Subjects with Thymidine Kinase 2 (TK2) Deficiency

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510763-35-00

Enrollment

Registered

2024-07-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organic compound

Brief summary

To evaluate the efficacy of dT+dC in adults with TK2d.

Detailed description

To evaluate the safety of dT+dC in adults with TK2d.

Interventions

DRUGdoxecitine and doxribtimine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of dT+dC in adults with TK2d.	—

Secondary

Measure	Time frame
To evaluate the safety of dT+dC in adults with TK2d.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026